What’s driving the Immutep share price in June?

Can the ASX healthcare share maintain its momentum this month?

| More on:
a doctor in a white coat sits at her computer with finger on mouth thinking about something in her office with medical equipment in the background.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • Immutep shares resurfaced last month setting up a nice trend for the start of June 
  • Investors have pushed the stock around over the past six months despite a number of positive updates
  • Over the last 12 months, the Immutep share price has tumbled by more than 40%

The Immutep Ltd (ASX: IMM) share price has gyrated in recent months, having slumped from a 52-week high of 71 cents back in November to close Friday’s session at 37 cents.

Investors pushed the stock to 52-week lows by April this year, when it then found buyers at the 30.5 cents mark, and it has been on an upward ascent since.

As seen below, the Immutep share price has gained around 7% in the past month, despite the period of volatility leading up to this point.

TradingView Chart

What tailwinds are there for the Immutep share price in June?

The Immutep share price came out of May in a healthy position, having strengthened throughout the month. Investors pushed the stock around 24% higher in May following two updates regarding the company’s lead drug candidate, efti.

Study readouts are key in the growth narrative of biotech stocks like Immutep. For the company, news around its etfi compound has been paramount for its share price appreciation.

Most recently, Immutep advised of another phase 2 trial update regarding the use of etfi as a combination therapy with the drug Keytruda (pembrolizumab).

The trial, called TACTI-002, “met its primary objective for 1st line non-small cell lung cancer (NSCLC) patients in a PD-L1 all-comer Phase II clinical trial conducted in collaboration with MSD”, the company said.

[The] “combination of efti plus pembrolizumab shows favourable anti-tumour activity…[dosages] were safe and well tolerated, with a safety profile that is consistent with that observed in previously reported studies,” it added.

Speaking on the results, Immutep CEO Marc Voigt said:

We are delighted that patient outcomes are improved with the combination of efti plus pembrolizumab across different patient groups. The data is encouraging for patients, as there is an unmet medical need particularly for those with NSCLC with no or low PD-L1 expression.

Immutep was also on the radar of Pengana High Conviction portfolio manager James McDonald when he spoke to The Motley Fool’s Tony Yoo last month.

McDonald said there was “very substantial upside” to be had in the Immutep share price should the company be able to successfully tap into its US$50 billion addressable market.

In the last 12 months, the Immutep share price has tumbled by more than 43% and is also down around 24% this year to date.

Motley Fool contributor Zach Bristow has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Five healthcare workers standing together and smiling.
Healthcare Shares

Medibank share price dips despite dividend boost

The healthcare insurer will pay its biggest final dividend since 2019.

Read more »

Three medical staffers sit at a table and chat happily wearing hospital scrubs
Earnings Results

Pro Medicus share price fails to fly on 44% profit leap

Here's how Pro Medicus dialled up the profits in FY22.

Read more »

A CSL scientist looking through a telescope in a lab
Earnings Results

Telix share price slides despite 726% revenue boost

Investors may be thinking the pharmaceutical company's valuation has peaked after the stock price doubled over the past three months.

Read more »

Broker looking at the share price on her laptop with green and red points in the background.
Broker Notes

Broker gives its verdict on the CSL share price post-FY22 results

Here's what this broker is saying about the CSL share price...

Read more »

An older woman tries to listen by cupping her ear.
Healthcare Shares

Guess which ASX biotech share is soaring 32% on a ‘landmark’ FDA ruling

What a day it has become for this small-cap healthcare company.

Read more »

Two happy scientists analysing test results.
Dividend Investing

Everything you need to know about the latest CSL dividend

Own CSL shares? Here's the details regarding its latest dividend.

Read more »

A businesswoman exhales a deep sigh after receiving bad news, and gets on with it.
Healthcare Shares

CSL share price drops despite expectations of growth in FY23

Investors are punishing CSL. What's going on?

Read more »

ventilator mask
Healthcare Shares

Why ‘the outlook is very bullish’ for the Resmed share price: Tribeca

ResMed has been rated as a buy by Tribeca.

Read more »